Looking beyond cancer, Twentyeight-Seven Therapeutics bumps up series A to $82M+

3D medical background with DNA strand
Rather than target the RNA itself, Twentyeight-Seven Therapeutics is developing drugs that focus on RNA-modulating proteins. (kirstypargeter/iStock/Getty Images Plus/Getty Images)

Twentyeight-Seven Therapeutics launched last September with $65 million to develop cancer treatments that modify microRNA to boost the levels of tumor-suppressing genes. Now, with a series A extension of $17.75 million, the company will develop programs aimed at other types of RNA as well as apply its work in disease areas other than cancer. 

The company was founded in 2016 around technology from four Harvard Medical School professors across multiple disciplines: biological chemistry, molecular pharmacology and RNA medicine. Richard Gregory, Ph.D.; Frank Slack, Ph.D.; Piotr Sliz, Ph.D.; and George Daley, M.D., Ph.D., dean of the faculty of medicine, have worked together for years on the role of noncoding RNAs in disease and identifying related protein targets. 

Rather than target the RNA itself, Twentyeight-Seven is developing drugs that focus on RNA-modulating proteins. Its lead program is a small molecule that inhibits Lin28, a protein that reduces levels of Let-7, a microRNA that suppresses tumors. By targeting Lin28, Twentyeight-Seven hopes to boost Let-7, thereby curbing the translation of oncogenes within cells. 

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

RELATED: 28-7 Therapeutics raises $65M for cancer drugs aimed at tumor-suppressing RNA

The original $65 million series A came from Twentyeight-Seven's founding investor, MPM Capital, as well as Novartis Venture Fund, Johnson & Johnson Innovation, Vertex Ventures HC, Longwood Fund and Astellas Venture Management. Since then, the company has moved into new digs in Watertown, Massachusetts. 

Of the new funding, $15 million comes from Sofinnova Partners with the rest coming from Osage University Partners. It will support technology development and ramp up Twentyeight-Seven's cancer programs. 

“Sofinnova Partners is known for being a company-builder, with a strong focus on teams and science. With Sofinnova’s participation, we are able to work on proteins that regulate additional classes of RNA, including mRNA, as well as to leverage the programs into indications outside of oncology,” said Twentyeight-Seven CEO Kazumi Shiosaki, Ph.D., in a statement.

Suggested Articles

Genentech committed $200 million in upfront and near-term payments, plus up to $515 million in more distant milestones, for the exclusive rights.

Netherlands-based biotech Vico Therapeutics has signed up biopharma veteran Rupert Sandbrink, M.D., Ph.D., as its new chief medical officer.

French biotech Genfit is cutting its way out of its phase 3 NASH disaster in the summer and cresting two new units.